Finance
Semafore granted nearly $1 million to study small molecule SF1126 in multiple myeloma
Published in Blood Weekly, January 4th, 2007
This is the second clinical trial grant awarded to Semafore. The company recently announced receipt of a grant from Cancer Treatment Research Foundation (CTRF) to help fund a phase l trial of SF1126 in solid cancers. Both phase l trials are expected to commence in 2007.
The MMRF has awarded Semafore a $996,380 grant to help fund both the drug manufacturing and the patient costs of a phase l trial in relapsed and refractory multiple myeloma patients. The...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2007-01-04)
More Articles from Blood Weekly
- Blood Substitutes
New data from University of California, Department of Bioengineering illuminate research in blood substitutes - Influenza
Research from University of California provide new insights into influenza - Sepsis
Researchers from Sapporo Medical University, Department of Anesthesiology describe findings in sepsis - Sepsis Epidemiology
Scientists at National Institute of Allergy and Infectious Disease target sepsis epidemiology - Sepsis Epidemiology
Studies from Curtin University of Technology have provided new data on sepsis epidemiology - Sepsis Epidemiology
Westmead Hospital publishes research in sepsis epidemiology - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
